Peptio

Semaglutide

Also known as Ozempic, Wegovy, Rybelsus

A GLP-1 receptor agonist approved in the US and EU for type 2 diabetes and weight management, with cardiovascular and kidney outcome trials.

Semaglutide is a modified analogue of GLP-1, a hormone released from the gut after eating, and it activates the GLP-1 receptor. It is an approved medicine from Novo Nordisk, approved under three brand names that all contain the same molecule. In the US, Ozempic is an injection and, on a label shared with Rybelsus, also a tablet, both for type 2 diabetes; Rybelsus is a tablet for type 2 diabetes; and Wegovy, as an injection or a tablet, is for weight management and cardiovascular risk reduction, and in the US, as an injection, for MASH with liver fibrosis.

What it is

The US label for the tablets describes semaglutide as a GLP-1 analogue with 94% sequence homology to human GLP-1. Its lysine at position 26 carries a hydrophilic spacer and a C18 fatty diacid, which binds albumin; the label calls that binding the main mechanism that prolongs its action. Position 8 is modified to protect it from breakdown by the enzyme DPP-4. Its peptide backbone is made by yeast fermentation.

The fatty-acid chain is not an amino acid, so no sequence written in the twenty standard one-letter codes describes that structure, which is why none is shown on this page. The molecular weight given here, 4113.58, and the formula C187H291N45O59 are the label's own.

Where it is approved

In the US, each date below is from the electronic signature page of FDA's letter.

  • Ozempic injection was approved on 5 December 2017 to improve glycaemic control in adults with type 2 diabetes (approval letter). It gained a cardiovascular indication in type 2 diabetes with established cardiovascular disease, based on SUSTAIN 6, on 16 January 2020 (supplement approval letter), and a kidney indication in type 2 diabetes with chronic kidney disease on 28 January 2025 (supplement approval letter).
  • Rybelsus tablets were approved on 20 September 2019 for type 2 diabetes (approval letter), and gained a cardiovascular indication in type 2 diabetes at high risk on 17 October 2025 (supplement approval letter).
  • Wegovy injection was approved on 4 June 2021 for chronic weight management in adults (approval letter), and was extended to children aged 12 and older with obesity on 23 December 2022 (supplement approval letter). It gained cardiovascular risk reduction, based on SELECT, on 8 March 2024 (supplement approval letter), and MASH with moderate to advanced fibrosis on 15 August 2025, under accelerated approval (supplement approval letter).
  • Wegovy tablets were approved on 22 December 2025 (approval letter).

An accelerated approval rests on a surrogate, here liver biopsy findings. FDA's MASH letter requires a 240-week randomised trial in MASH to show clinical benefit, including on progression to cirrhosis, with completion scheduled for June 2029.

In the EU, all three products are authorised, each with its own product information: Ozempic from 8 February 2018, Rybelsus from 3 April 2020 and Wegovy from 6 January 2022. The EU Wegovy indication is weight management. Cardiovascular results are described in its product information but are not listed as an indication, and MASH does not appear in its indication. Only FDA and EMA were checked for this page.

The thyroid warning, and where the US and the EU differ

Every US label carries a boxed warning. In rodents, semaglutide causes thyroid C-cell tumours at clinically relevant exposures, and it is unknown whether it causes such tumours, including medullary thyroid carcinoma, in humans. The US labels contraindicate it in people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2 (MEN 2).

The EU Wegovy product information's only contraindication is hypersensitivity to the active substance or its excipients. It describes the rodent tumours as "a class effect for GLP-1 receptor agonists" and says their "relevance for humans is considered to be low, but cannot be completely excluded." As with tirzepatide, the thyroid contraindication is a US position, not a universal one. FDA's Wegovy approval letter requires a medullary thyroid carcinoma registry-based case series of at least 15 years, to look for any increase in the US after semaglutide's introduction for obesity.

The thyroid finding is not the only warning. The US Wegovy label also carries warnings and precautions on acute pancreatitis, acute gallbladder disease, hypoglycaemia with insulin or insulin secretagogues, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, hypersensitivity reactions, diabetic retinopathy complications in people with type 2 diabetes, heart rate increase, and pulmonary aspiration during general anaesthesia or deep sedation. On pregnancy, its highlights state "May cause fetal harm". In the EU Wegovy product information, as label data, adjudication-confirmed acute pancreatitis was reported in 0.2% on semaglutide and under 0.1% on placebo in the phase 3a trials, and in 0.2% and 0.3% in SELECT. In STEP 2, in people with type 2 diabetes, it reports clinically significant hypoglycaemia in 6.2% on semaglutide against 2.5% on placebo.

The two regulators also differ on the eye. The EU product information for all three products carries a warning on non-arteritic anterior ischaemic optic neuropathy, which it bases on epidemiological studies, and says that sudden loss of vision should lead to an eye examination and that semaglutide should be stopped if NAION is confirmed. The three US labels read for this page do not mention it. The observational evidence behind the warning is set out under the risks above.

The US Wegovy label lists among its recent major changes the removal, in 01/2026, of its warning on "Suicidal Behavior and Ideation", the same removal made on the tirzepatide label.

What is not known

SELECT showed a reduction in a composite of heart attack, stroke and cardiovascular death in people without diabetes. The US label is explicit that this is not a finding on cardiovascular death alone, and that the effect on heart failure has not been established.

The weight trials on this page ran for 72 weeks or less, and the withdrawal trial followed people for 48 weeks after switching. They show that weight was regained after treatment stopped, within that time. They say nothing about what follows.

Whether semaglutide raises the risk of NAION is unsettled. Every study is observational. Both meta-analyses found an association in type 2 diabetes and none shown in overweight or obesity, and one rated the evidence low to very low certainty.

Every randomised trial on this page was funded by Novo Nordisk, except STEP 4 and PIONEER 1, whose abstracts do not name a funder.

Compounded and "research" semaglutide

Semaglutide injection was added to FDA's drug shortage list in March 2022 for Wegovy and August 2022 for Ozempic. In a declaratory order dated 21 February 2025, FDA determined that the shortage was resolved, and set the end of its enforcement discretion for compounders: 22 April 2025 for state-licensed pharmacists or physicians under section 503A of the FD&C Act, and 22 May 2025 for outsourcing facilities under section 503B. FDA's page on its compounding policies, current as of 1 April 2026, says semaglutide does not appear on the 503B bulks list or on its drug shortage list.

FDA states that as of 31 May 2026 it had received 990 reports of adverse events associated with compounded semaglutide. It adds that adverse events from compounded versions are likely under-reported, and that it is not always possible to determine whether an event resulted from the drug. The same page says some compounders may use salt forms, semaglutide sodium and semaglutide acetate, which it calls "different active ingredients than are used in the approved drugs", and that FDA has warned companies selling unapproved semaglutide falsely labelled for research purposes or not for human consumption. It also reports counterfeit Ozempic in the US.

Every trial result on this page describes Novo Nordisk's product given under trial conditions. None of it describes a compounded product, a salt form or one sold for research use.

Anti-doping

WADA's Prohibited List could not be retrieved for this page, so the page says nothing about semaglutide's status in sport, in either direction.

What the research shows

Each statement below is labelled with the strongest kind of study supporting it, and links to that study.

  • Human randomised trialSupportive / High confidence

    In a phase 3 trial of 1961 adults with obesity, or overweight with a weight-related condition, and without diabetes, body weight fell more with semaglutide 2.4 mg than with placebo over 68 weeks.

    STEP 1 randomised 1961 adults with a BMI of 30 or more, or 27 or more with at least one weight-related coexisting condition, and without diabetes, in a 2:1 ratio to semaglutide 2.4 mg or placebo, both with a lifestyle intervention, for 68 weeks. Under the primary estimand, which assessed effects regardless of treatment discontinuation or rescue interventions, mean body weight changed by -14.9% with semaglutide and -2.4% with placebo, an estimated difference of -12.4 percentage points (95% CI -13.4 to -11.5). A reduction of 5% or more was reached by 86.4% against 31.5%, and of 15% or more by 50.5% against 4.9%. More participants stopped treatment because of gastrointestinal events with semaglutide (4.5%) than with placebo (0.8%).

    Tested in humans under randomised, controlled conditions.

    • The figures come from the published abstract only. The full text was not read for this page.
    • The trial was funded by Novo Nordisk, the manufacturer.
    • The results describe Novo Nordisk's product given under trial conditions. They do not describe compounded semaglutide or any product sold for research use.

    PMID 33567185

  • Human randomised trialSupportive / High confidence

    In a phase 3 trial of 1210 adults with overweight or obesity and type 2 diabetes, body weight fell more with semaglutide 2.4 mg than with placebo over 68 weeks.

    STEP 2 randomised 1210 adults with a BMI of at least 27 and type 2 diabetes, with glycated haemoglobin of 7 to 10%, in a 1:1:1 ratio to semaglutide 2.4 mg, semaglutide 1.0 mg or placebo, with a lifestyle intervention, for 68 weeks. Mean body weight changed by -9.6% with semaglutide 2.4 mg and -3.4% with placebo, an estimated difference of -6.2 percentage points (95% CI -7.3 to -5.2). A reduction of at least 5% was reached by 68.8% against 28.5%. Gastrointestinal adverse events were reported in 63.5% with semaglutide 2.4 mg, 57.5% with 1.0 mg and 34.3% with placebo.

    Tested in humans under randomised, controlled conditions.

    • The figures come from the published abstract only.
    • The trial was funded by Novo Nordisk.
    • STEP 1 and STEP 2 enrolled different populations. Their results are not a comparison of people with and without diabetes within one trial.

    PMID 33667417

  • Human randomised trialSupportive / High confidence

    In a phase 3 withdrawal trial, people who switched from semaglutide to placebo regained weight, while those who continued kept losing it.

    STEP 4 gave 902 adults with obesity, or overweight with a weight-related condition, and without diabetes, semaglutide during a 20-week run-in. The 803 who reached the 2.4 mg maintenance dose, and who had lost a mean of 10.6% of their weight during the run-in, were then randomised 2:1 to continue semaglutide or switch to placebo for a further 48 weeks. From week 20 to week 68, body weight changed by -7.9% with continued semaglutide and +6.9% after the switch to placebo, a difference of -14.8 percentage points (95% CI -16.0 to -13.5).

    Tested in humans under randomised, controlled conditions.

    • The figures come from the published abstract only.
    • Only people who tolerated the full dose during the run-in were randomised, so the results describe that group.
    • Follow-up ended 48 weeks after the switch. The abstract does not say what happened after that.
    • The abstract does not name a funder.

    PMID 33755728

  • Human randomised trialSupportive / Moderate confidence

    In a trial of 201 adolescents aged 12 to under 18, mostly with obesity, BMI fell more with semaglutide 2.4 mg than with placebo over 68 weeks.

    STEP TEENS randomised 201 adolescents with obesity, or overweight with a weight-related condition, in a 2:1 ratio to semaglutide 2.4 mg or placebo, with a lifestyle intervention, for 68 weeks. All but one had obesity. The mean change in BMI was -16.1% with semaglutide and, as printed, 0.6% with placebo, an estimated difference of -16.7 percentage points (95% CI -20.3 to -13.2). Gastrointestinal adverse events occurred in 62% against 42%, and cholelithiasis in five participants (4%) on semaglutide and none on placebo.

    Tested in humans under randomised, controlled conditions.

    • The figures come from the published abstract only.
    • A trial of 201 participants over 68 weeks cannot describe long-term effects on growth or development.
    • The trial was funded by Novo Nordisk.

    PMID 36322838

  • Human randomised trialSupportive / Moderate confidence

    As a 25 mg tablet, semaglutide reduced body weight more than placebo over 64 weeks in adults with obesity or overweight and without diabetes.

    OASIS 4 randomised adults without diabetes who had a BMI of 30 or more, or 27 or more with at least one obesity-related complication, in a 2:1 ratio to oral semaglutide 25 mg or placebo, with lifestyle interventions: 205 to semaglutide and 102 to placebo. The estimated mean change in body weight at week 64 was -13.6% with oral semaglutide and -2.2% with placebo, an estimated difference of -11.4 percentage points (95% CI -13.9 to -9.0). Gastrointestinal adverse events occurred in 74.0% against 42.2%.

    Tested in humans under randomised, controlled conditions.

    • The figures come from the published abstract only, which does not name the estimand behind the figures.
    • The trial ran at 22 sites in four countries.
    • The trial was funded by Novo Nordisk.

    PMID 40934115

  • Human randomised trialSupportive / Moderate confidence

    In the one published trial comparing them in obesity, weight fell less with semaglutide than with tirzepatide over 72 weeks.

    SURMOUNT-5 randomised 751 adults with obesity and without type 2 diabetes, 1:1, to the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or of semaglutide (1.7 mg or 2.4 mg) for 72 weeks. The least-squares mean change in weight was -13.7% (95% CI -14.9 to -12.6) with semaglutide and -20.2% (95% CI -21.4 to -19.1) with tirzepatide. Gastrointestinal events were the most common adverse events in both groups.

    Tested in humans under randomised, controlled conditions.

    • The trial was open label, so participants and investigators knew which drug was given.
    • It was funded by Eli Lilly, the maker of tirzepatide.
    • The figures come from the published abstract only.

    PMID 40353578

  • Human randomised trialSupportive / High confidence

    In adults with type 2 diabetes managed by diet and exercise alone, semaglutide lowered HbA1c more than placebo, as an injection and as a tablet.

    SUSTAIN 1 randomised 388 treatment-naive adults with type 2 diabetes and HbA1c of 7.0 to 10.0% to semaglutide 0.5 mg or 1.0 mg, or placebo, for 30 weeks, analysed in everyone who received at least one dose, with the two placebo groups pooled. From a mean baseline of 8.05%, HbA1c fell by 1.45% and 1.55% with the two doses, estimated differences against placebo of -1.43% and -1.53%. PIONEER 1 randomised 703 adults to oral semaglutide 3 mg, 7 mg or 14 mg, or placebo, for 26 weeks. Under the treatment policy estimand, regardless of stopping treatment or rescue medication, the placebo-adjusted differences in HbA1c were -0.6%, -0.9% and -1.1%.

    Tested in humans under randomised, controlled conditions.

    • The figures come from the published abstracts only.
    • Both trials enrolled people not yet on glucose-lowering medicine and were short, 30 and 26 weeks.
    • SUSTAIN 1 was funded by Novo Nordisk. The PIONEER 1 abstract does not state its funder.

    PMID 28110911PMID 31186300

  • Human randomised trialSupportive / High confidence

    In 17,604 adults with cardiovascular disease and overweight or obesity but without diabetes, semaglutide 2.4 mg reduced major adverse cardiovascular events compared with placebo.

    SELECT enrolled people aged 45 or older with preexisting cardiovascular disease, a BMI of 27 or more and no history of diabetes, and randomised them 1:1 to semaglutide 2.4 mg or placebo: 8803 and 8801. The primary end point, a composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke, occurred in 6.5% on semaglutide and 8.0% on placebo over a mean follow-up of 39.8 months (hazard ratio 0.80, 95% CI 0.72 to 0.90). Adverse events led to permanent discontinuation in 16.6% on semaglutide and 8.2% on placebo.

    Tested in humans under randomised, controlled conditions.

    • The US Wegovy label notes that cardiovascular death was the first confirmatory secondary end point and that superiority was not confirmed. The result is for the composite, not for death.
    • The label also states: 'Effect on heart failure has not been established.'
    • The figures come from the published abstract and the US label. The trial was funded by Novo Nordisk.

    PMID 37952131fda-label-wegovy-2026-06

  • Human randomised trialSupportive / Moderate confidence

    In adults with type 2 diabetes at high cardiovascular risk, injected semaglutide was noninferior to placebo for major adverse cardiovascular events, with fewer events, and more retinopathy complications.

    SUSTAIN-6 randomised 3297 patients with type 2 diabetes to semaglutide 0.5 mg or 1.0 mg, or placebo, for 104 weeks; 83.0% had established cardiovascular disease, chronic kidney disease or both. The primary composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke occurred in 6.6% with semaglutide and 8.9% with placebo (hazard ratio 0.74, 95% CI 0.58 to 0.95). Retinopathy complications were significantly more frequent with semaglutide (hazard ratio 1.76, 95% CI 1.11 to 2.78).

    Tested in humans under randomised, controlled conditions.

    • The trial was designed to test noninferiority, to rule out excess cardiovascular risk. Its P value is for noninferiority.
    • Rates of cardiovascular death were similar in the two groups.
    • The figures come from the published abstract only. The trial was funded by Novo Nordisk.

    PMID 27633186

  • Human randomised trialSupportive / High confidence

    In SOUL, oral semaglutide reduced major adverse cardiovascular events compared with placebo in adults with type 2 diabetes and cardiovascular or kidney disease.

    SOUL randomised 9650 people aged 50 or older with type 2 diabetes and known atherosclerotic cardiovascular disease, chronic kidney disease or both to oral semaglutide, at a maximal dose of 14 mg, or placebo, on top of standard care. Over a mean follow-up of 47.5 months, a major adverse cardiovascular event occurred in 12.0% on oral semaglutide and 13.8% on placebo (hazard ratio 0.86, 95% CI 0.77 to 0.96). The confirmatory secondary outcomes, including major kidney disease events, did not differ significantly.

    Tested in humans under randomised, controlled conditions.

    • The figures come from the published abstract only. The trial was funded by Novo Nordisk.
    • The SOUL abstract reports gastrointestinal disorders in 5.0% and 4.4% without saying how they were counted, so the figure is not used on this page as a measure of how common gastrointestinal side effects are.

    PMID 40162642

  • Human randomised trialNo effect found / Moderate confidence

    An earlier trial of oral semaglutide, PIONEER 6, showed it was not worse than placebo for major adverse cardiovascular events, and did not show it was better.

    PIONEER 6 randomised 3183 patients with type 2 diabetes at high cardiovascular risk to oral semaglutide or placebo. It was designed to rule out an 80% excess in cardiovascular risk. Over a median of 15.9 months, major adverse cardiovascular events occurred in 3.8% on oral semaglutide and 4.8% on placebo (hazard ratio 0.79, 95% CI 0.57 to 1.11). The confidence interval includes no difference, so the trial established noninferiority, not a reduction.

    Tested in humans under randomised, controlled conditions.

    • The figures come from the published abstract only. The trial was funded by Novo Nordisk.
    • A short trial with few events. SOUL, larger and longer, is the oral trial that tested for a reduction.

    PMID 31185157

  • Human randomised trialSupportive / High confidence

    In adults with type 2 diabetes and chronic kidney disease, semaglutide 1.0 mg reduced major kidney disease events compared with placebo.

    FLOW randomised 3533 patients with type 2 diabetes and chronic kidney disease, defined by eGFR and urinary albumin-to-creatinine ratio, to semaglutide 1.0 mg or placebo. The primary outcome combined kidney failure, a fall of at least 50% in eGFR, and death from kidney-related or cardiovascular causes. Over a median follow-up of 3.4 years it occurred less often with semaglutide (331 against 410 first events, hazard ratio 0.76, 95% CI 0.66 to 0.88). Death from cardiovascular causes was also lower (hazard ratio 0.71, 95% CI 0.56 to 0.89).

    Tested in humans under randomised, controlled conditions.

    • The trial was stopped early, after early cessation was recommended at a prespecified interim analysis. The abstract does not say on what grounds.
    • The figures come from the published abstract only. The trial was funded by Novo Nordisk.

    PMID 38785209

  • Human randomised trialSupportive / Moderate confidence

    In adults with MASH and moderate or advanced liver fibrosis, semaglutide 2.4 mg improved liver biopsy findings more than placebo at 72 weeks, in an interim analysis.

    ESSENCE assigned 1197 patients with biopsy-confirmed MASH and fibrosis stage 2 or 3, in a 2:1 ratio, to semaglutide 2.4 mg or placebo for 240 weeks. A planned interim analysis at week 72 in the first 800 patients found resolution of steatohepatitis without worsening of fibrosis in 62.9% on semaglutide and 34.3% on placebo, and reduction in fibrosis without worsening of steatohepatitis in 36.8% against 22.4%.

    Tested in humans under randomised, controlled conditions.

    • These are liver biopsy findings, a surrogate. Whether they translate into fewer cases of cirrhosis, liver failure or death is what the rest of the trial is meant to show.
    • The US approval for MASH is an accelerated approval on this basis; FDA states that continued approval may depend on a confirmatory trial.
    • The figures come from the published abstract only. The trial was funded by Novo Nordisk.

    PMID 40305708fda-approval-wegovy-mash-2025

  • Human randomised trialSupportive / Moderate confidence

    In 529 people with heart failure with preserved ejection fraction and obesity, semaglutide 2.4 mg improved symptoms and physical limitations more than placebo over 52 weeks.

    STEP-HFpEF randomised 529 patients with heart failure with preserved ejection fraction and a BMI of 30 or higher to semaglutide 2.4 mg or placebo for 52 weeks. The Kansas City Cardiomyopathy Questionnaire clinical summary score improved by 16.6 points with semaglutide and 8.7 with placebo (estimated difference 7.8 points, 95% CI 4.8 to 10.9), and body weight changed by -13.3% against -2.6%. The 6-minute walk distance increased by 21.5 m against 1.2 m.

    Tested in humans under randomised, controlled conditions.

    • The trial measured symptoms, function and weight, not heart failure events or death.
    • Heart failure is not an indication on the US labels read for this page, and the US Wegovy label states that its effect on heart failure has not been established.
    • The figures come from the published abstract only. The trial was funded by Novo Nordisk.

    PMID 37622681

Reported and theoretical risks

  • Human RCTmoderate

    Gastrointestinal adverse events, including nausea, diarrhoea and vomiting

    In STEP 1, nausea and diarrhoea were the most common adverse events with semaglutide, described as typically transient and mild to moderate, and 4.5% stopped treatment because of gastrointestinal events against 0.8% on placebo. In STEP 2, gastrointestinal adverse events were reported in 63.5% with semaglutide 2.4 mg against 34.3% with placebo, and in OASIS 4, with the 25 mg tablet, in 74.0% against 42.2%. The EU Wegovy product information pools the four STEP 1 to 4 trials, as label data: over 68 weeks, nausea occurred in 43.9% on semaglutide against 16.1% on placebo, diarrhoea in 29.7% against 15.9%, vomiting in 24.5% against 6.3% and constipation in 24.2% against 11.1%.

  • Human RCTserious

    Diabetic retinopathy complications in people with type 2 diabetes

    In SUSTAIN-6, retinopathy complications (vitreous haemorrhage, blindness, or conditions needing treatment with an intravitreal agent or photocoagulation) were significantly more frequent with semaglutide than with placebo (hazard ratio 1.76, 95% CI 1.11 to 2.78). The EU Wegovy product information describes the same trial as label data: adjudicated events occurred in 3.0% on semaglutide against 1.8% on placebo, in insulin-treated patients with known diabetic retinopathy. The US labels carry a warning on diabetic retinopathy complications in patients with type 2 diabetes.

  • Human obs.serious

    Non-arteritic anterior ischaemic optic neuropathy (NAION), a cause of sudden vision loss

    The observational studies do not agree. A cohort at one US academic centre reported a higher risk with semaglutide than with other medicines in type 2 diabetes (hazard ratio 4.28, 95% CI 1.62 to 11.29) and in overweight or obesity (hazard ratio 7.64, 95% CI 2.21 to 26.36). A Danish and Norwegian registry study in type 2 diabetes found a pooled hazard ratio of 2.81 (95% CI 1.67 to 4.75) against SGLT-2 inhibitors, an incidence rate difference of +1.41 per 10,000 person-years, and called the absolute risk low. A multinational records study reported no significant association in type 2 diabetes, obesity or both; in type 2 diabetes alone its hazard ratios at one and two years were 2.32 (95% CI 0.60 to 8.97) and 2.31 (0.86 to 6.17), with intervals too wide to exclude no effect. Two meta-analyses of observational studies have pooled these results. One, searching to August 2025, found no consistent overall increase, but a pooled hazard ratio of 1.70 (95% CI 1.10 to 2.64) in type 2 diabetes against 0.47 (0.19 to 1.13) in obesity or overweight, and rated the evidence low to very low certainty. The other, searching to May 2026 and pooling eight cohorts, found a higher risk overall (relative effect 1.93, 95% CI 1.22 to 3.08) and in diabetes (1.84, 1.21 to 2.80), and no significant association in overweight or obesity (1.68, 0.72 to 3.91). Both meta-analyses therefore found an association in diabetes and none shown in overweight or obesity. The EU Wegovy product information lists NAION as a very rare adverse reaction and says epidemiological studies suggest about one additional case per 10,000 person-years of treatment in adults with type 2 diabetes.

  • Human RCTmoderate

    Gallbladder disease, including gallstones

    In STEP TEENS, cholelithiasis occurred in five adolescents (4%) on semaglutide and none on placebo. The EU Wegovy product information, pooling the adult weight trials as label data, reports cholelithiasis in 1.6% on semaglutide, leading to cholecystitis in 0.6%, against cholelithiasis in 1.1% and cholecystitis in 0.3% on placebo. The US labels carry a warning on acute gallbladder disease.

Regulatory status

Status differs by country and changes over time. Each entry is dated and sourced.

  • USFDAapproved

    Wegovy, as an injection and as a tablet, on one label revised 06/2026. The injection is indicated, with a reduced calorie diet and increased physical activity, to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight; to reduce excess body weight and maintain weight reduction long term in adults and children aged 12 and older with obesity, and in adults with overweight and at least one weight-related comorbid condition; and, under accelerated approval, for noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3) in adults. The tablets carry the cardiovascular and adult weight indications. The label carries a boxed warning on thyroid C-cell tumours in rodents.

    As of 4 October 2026. Source

  • USFDAapproved

    Ozempic injection, label revised 05/2026. Indicated alongside diet and exercise to improve glycaemic control in adults with type 2 diabetes; to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Same boxed warning. Not indicated for weight management.

    As of 4 October 2026. Source

  • USFDAapproved

    Rybelsus tablets and Ozempic tablets, on one label revised 1/2026. Indicated alongside diet and exercise to improve glycaemic control in adults with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk of them. Same boxed warning.

    As of 4 October 2026. Source

  • EUEMAapproved

    Wegovy, as an injection and, in the current product information, as tablets, first authorised on 6 January 2022, for weight management in adults with a BMI of 30 or more, or 27 or more with at least one weight-related comorbidity, and in adolescents aged 12 and above with obesity and body weight above 60 kg. Its indication text points to section 5.1 for trial results on cardiovascular risk reduction and obesity-related heart failure, without listing them as indications. Its only contraindication is hypersensitivity.

    As of 4 October 2026. Source

  • EUEMAapproved

    Ozempic injection, first authorised on 8 February 2018, for adults with insufficiently controlled type 2 diabetes, alongside diet and exercise, alone when metformin is unsuitable or with other diabetes medicines. Its indication text points to section 5.1 for results on cardiovascular disease and kidney events. Its only contraindication is hypersensitivity.

    As of 4 October 2026. Source

  • EUEMAapproved

    Rybelsus tablets, first authorised on 3 April 2020, for adults with insufficiently controlled type 2 diabetes, alongside diet and exercise, alone when metformin is unsuitable or with other diabetes medicines. Its indication text points to section 5.1 for results on cardiovascular events.

    As of 4 October 2026. Source

Research and analysis

  • RetatrutideInvestigational triple receptor agonist with published phase 3 trials
  • TirzepatideTirzepatide is a dual GIP and GLP-1 receptor agonist, approved in the US and the EU for type 2 diabetes and for weight management

Sources

  1. 1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity.. The New England Journal of Medicine. 2021. PubMed 33567185
  2. 2. Davies M et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.. The Lancet. 2021. PubMed 33667417
  3. 3. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.. JAMA. 2021. PubMed 33755728(open access)
  4. 4. Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity.. The New England Journal of Medicine. 2022. PubMed 36322838(open access)
  5. 5. Wharton S et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.. The New England Journal of Medicine. 2025. PubMed 40934115
  6. 6. Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.. The New England Journal of Medicine. 2025. PubMed 40353578
  7. 7. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.. The Lancet Diabetes & Endocrinology. 2017. PubMed 28110911
  8. 8. Aroda VR et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes.. Diabetes Care. 2019. PubMed 31186300
  9. 9. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.. The New England Journal of Medicine. 2023. PubMed 37952131
  10. 10. WEGOVY (semaglutide) injection and tablets. Prescribing Information, revised 06/2026 (NDA 215256 and NDA 218316). U.S. Food and Drug Administration, Drugs@FDA. 2026. View source(open access)
  11. 11. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.. The New England Journal of Medicine. 2016. PubMed 27633186
  12. 12. McGuire DK et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.. The New England Journal of Medicine. 2025. PubMed 40162642
  13. 13. Husain M et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.. The New England Journal of Medicine. 2019. PubMed 31185157
  14. 14. Perkovic V et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.. The New England Journal of Medicine. 2024. PubMed 38785209
  15. 15. Sanyal AJ et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.. The New England Journal of Medicine. 2025. PubMed 40305708
  16. 16. NDA 215256/S-024 supplement approval letter, Wegovy MASH indication (accelerated approval), August 15, 2025. U.S. Food and Drug Administration. 2025. View source(open access)
  17. 17. Kosiborod MN et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.. The New England Journal of Medicine. 2023. PubMed 37622681
  18. 18. Wegovy: EPAR, Product Information (Annex I, Summary of Product Characteristics). European Medicines Agency. 2026. View source(open access)
  19. 19. OZEMPIC (semaglutide) injection, for subcutaneous use. Prescribing Information, revised 05/2026 (NDA 209637, S-038). U.S. Food and Drug Administration, Drugs@FDA. 2026. View source(open access)
  20. 20. Hathaway JT et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.. JAMA Ophthalmology. 2024. PubMed 38958939(open access)
  21. 21. Simonsen E et al. Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish-Norwegian cohort study.. Diabetes, Obesity and Metabolism. 2025. PubMed 40098249(open access)
  22. 22. Chou CC et al. Association between Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy: A Multinational Population-Based Study.. Ophthalmology. 2025. PubMed 39491755
  23. 23. Abdelaal A et al. Semaglutide and the Risk of Nonarteritic Ischemic Optic Neuropathy: A Systematic Review and Certainty of Evidence Meta-Analysis.. Ophthalmology. 2026. PubMed 41692115
  24. 24. Khani E et al. Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis.. Journal of Clinical Pharmacology. 2026. PubMed 42612051(open access)
  25. 25. RYBELSUS (semaglutide) tablets and OZEMPIC (semaglutide) tablets, for oral use. Prescribing Information, revised 1/2026 (NDA 213051, S-030). U.S. Food and Drug Administration, Drugs@FDA. 2026. View source(open access)
  26. 26. Ozempic: EPAR, Product Information (Annex I, Summary of Product Characteristics). European Medicines Agency. 2026. View source(open access)
  27. 27. Rybelsus: EPAR, Product Information (Annex I, Summary of Product Characteristics). European Medicines Agency. 2026. View source(open access)